Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag (MALS verified)
分子別名（Synonym）
IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,Interleukin-17F,Cytokine ML-1,IL17A＆IL17F
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag (ILF-H52W6) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F) (Accession # Q16552-1 (IL-17A) & Q96PD4-1 (IL-17F)). Two sequential affinity purification steps were used to ensure exact 1:1 molar ratio of IL17A＆IL17F heterodimer.
Predicted N-terminus: Trp (IL-17A) & His (IL-17F)
蛋白結(jié)構(gòu)（Molecular Characterization）
Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, produced by co-expression of IL-17A and IL-17F, has a calculated MW of 18.5 kDa (IL-17A) and 16.8 kDa (IL-17F). Subunit IL-17A is fused with a Twin Strep tag at the N-terminus and subunit IL-17F is fused with a polyhistidine tag at the N-terminus. The protein migrates as 19-27 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
白細(xì)胞介素-17A（IL17A）也被稱為細(xì)胞毒性T淋巴細(xì)胞相關(guān)抗原8（CTLA8），這是一種由活化的T細(xì)胞產(chǎn)生的促炎細(xì)胞因子。IL17A可以調(diào)節(jié)NF-κB和絲裂原活化蛋白激酶的活性。此外，IL17A可以刺激IL6和環(huán)氧化酶-2（PTGS2/COX-2）的表達(dá)，并增強(qiáng)一氧化氮（NO）的產(chǎn)生。此外，IL17A既有糖基化的形式，也有非糖基化形式。高水平的IL-17與幾種慢性炎癥性疾病有關(guān)，包括類風(fēng)濕性關(guān)節(jié)炎、銀屑病和多發(fā)性硬化癥。
關(guān)鍵字： IL-17A&IL-17F;IL-17A蛋白;IL-17F蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。